Content continues after advertisement

Research Note: Akkermansia muciniphila After Antimicrobial Administration

Sign in to Print/View PDF

The protective mucin barrier of the GI tract is preserved through a constant breakdown-production cycle. Akkermansia muciniphila is the predominant mucin-degrading microorganism in the human GI tract, with lower numbers found in humans with ulcerative colitis and Crohn’s disease. Treatment with this microorganism has been shown to improve markers of GI tract barrier function in rodents. This study measured the effects of oral A muciniphila administration on systemic markers of GI tract permeability and epithelial damage following antimicrobial treatment in healthy dogs. Results suggest that A muciniphila administration may have positive effects on epithelial damage in the GI tract caused by antimicrobial treatment. Further investigation is warranted for this potential probiotic.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2022 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy